Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Norway.
Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Norway; Division of Psychiatry, Diakonhjemmet Hospital, Norway.
J Affect Disord. 2023 Nov 1;340:886-892. doi: 10.1016/j.jad.2023.08.024. Epub 2023 Aug 12.
The present study reports on long-term outcomes of ABM over one year in self-reported and clinician-rated depression symptoms, anxiety symptoms, and relapse rates.
We conducted a double-blind randomized sham-controlled trial in 301 participants with recurrent major depression disorder between January 2015 and October 2016 (#NCT02658682). Participants were allocated to ABM or sham condition twice daily for 14 consecutive days. Long-term effects of ABM were assessed by BDI-II, HDRS and BAI at one-, six-, and 12-months follow-up. Relapse rates at 12-months follow-up were also assessed.
There was no long-term effect of ABM (as compared to sham) on clinician-rated depression symptoms, on anxiety symptoms, nor in relapse rates. By 12 months follow-up, there was a small effect on self-reported depression favoring ABM over sham.
The lack of an assessment-only condition hinders comparison to natural trajectories of depression symptoms.
The overall long-term effect of ABM was limited, and currently there is no convincing evidence for implementing this as a viable treatment option in clinical populations. We speculate if the sham condition should be replaced by another control condition when investigating the clinical utility of ABM.
本研究报告了经过一年以上的自我报告和临床医生评定的抑郁症状、焦虑症状和复发率,ABM 的长期结果。
我们于 2015 年 1 月至 2016 年 10 月期间对 301 名复发性重度抑郁症患者进行了一项双盲随机假对照试验(#NCT02658682)。参与者被分配到 ABM 或假条件下,每天两次,连续 14 天。在 1、6 和 12 个月的随访中,通过 BDI-II、HDRS 和 BAI 评估 ABM 的长期效果。还评估了 12 个月随访时的复发率。
与假治疗相比,ABM (与假治疗相比)在临床医生评定的抑郁症状、焦虑症状或复发率方面没有长期影响。在 12 个月的随访中,自我报告的抑郁症状有利于 ABM 而非假治疗,有较小的效果。
缺乏仅评估的条件限制了与抑郁症状自然轨迹的比较。
ABM 的总体长期效果有限,目前没有令人信服的证据将其作为一种可行的治疗选择在临床人群中实施。我们推测,如果在研究 ABM 的临床效用时,假治疗条件是否应被另一种对照条件所取代。